By Evan Chait, PT, LAc
Educational content only. This article does not provide medical advice, diagnosis, or treatment, and it is not guidance on starting, stopping, or dosing hormone therapy. Hormone therapy is prescription medical care that requires evaluation and ongoing management by a qualified physician.
I want to start by disagreeing slightly with the title of this article.
Hormone therapy is not a key. It is a medical intervention with a specific evidence base, a specific risk profile, and a population in whom it is appropriate and a population in whom it is not. The framing that treats it as a general-purpose optimisation tool for anyone experiencing fatigue or mental fog is the reason so much of the public conversation about it is unreliable.
What follows is the honest version. It is less exciting than the marketing, and it will be more useful to you.
What hormone therapy is actually for
Hormone therapy exists to treat hormone deficiency. That is the indication.
In menopausal women, the well-established indication is management of vasomotor symptoms — hot flushes and night sweats — and genitourinary symptoms, along with a role in bone density. In men, the indication is clinically diagnosed hypogonadism: symptoms together with repeatedly confirmed low morning testosterone, with the underlying cause investigated rather than assumed.
That last point matters more than it might appear. Low testosterone can be a consequence of obesity, sleep apnoea, poor sleep, chronic energy deficit, overtraining, certain medications, or pituitary pathology. Treating the number without investigating the cause can mean treating a symptom of something that needed different attention, and in the case of sleep apnoea, something that carries independent cardiovascular risk.
The cognition evidence, stated accurately
This is where public claims and published evidence diverge most sharply.
In women, the picture depends heavily on timing. The Women’s Health Initiative Memory Study, which examined older postmenopausal women initiating combined oestrogen and progestin therapy, found an increased incidence of dementia in the treatment group rather than a protective effect. That result reshaped the field.
A subsequent hypothesis — often called the timing hypothesis — proposes that initiation closer to menopause may carry a different risk-benefit profile than initiation many years afterward. This hypothesis has some supporting evidence and remains an area of active investigation rather than a settled conclusion.
What is more reliably established is indirect. Vasomotor symptoms disrupt sleep, and disrupted sleep impairs attention, working memory, and mood. Treating symptoms that are destroying someone’s sleep can improve how they think and function. That is a real and meaningful benefit. It is also a different claim from hormone therapy acting directly as a cognitive enhancer, and the two are frequently conflated.
In men, the most relevant evidence comes from the Testosterone Trials, which included a dedicated cognitive substudy in older men with low testosterone and age-associated memory impairment. That substudy did not find improvement in memory or other cognitive measures with testosterone treatment, even though other trials in the same programme found benefits in other domains.
Taken together: hormone therapy has documented benefits for specific symptoms in specific populations. Direct cognitive enhancement in people without deficiency is not among the well-supported ones, and in at least one large trial it was specifically looked for and not found.
Physical function
The physical side is somewhat clearer, with an important boundary.
In men with diagnosed hypogonadism, testosterone therapy has been associated with changes in body composition, generally increased lean mass and reduced fat mass. Effects on strength and physical performance have been more variable across trials, and the magnitude is often smaller than people expect from the body composition change.
The boundary is that these findings come from populations with deficiency. Extrapolating them to men with normal testosterone who want better performance is not supported, and supraphysiological use is a different intervention with a different risk profile that this article is not addressing.
In women, hormone therapy has an established role in bone density. Effects on muscle and physical function are less clearly characterised.
The risks are real and they are manageable
Hormone therapy is not unusually dangerous, but it is not free of risk, and any source presenting it as risk-free is not a source worth trusting.
For menopausal hormone therapy, the considerations include venous thromboembolism, stroke, and breast cancer risk, with the profile differing by formulation, route of administration, whether progestogen is included, age at initiation, and time since menopause. These distinctions are clinically significant and are the reason this requires a physician rather than a protocol.
For testosterone therapy, considerations include erythrocytosis, effects on fertility through suppression of the hypothalamic-pituitary-gonadal axis, prostate monitoring, and the fact that stopping after a prolonged period can leave someone with suppressed endogenous production. The fertility point in particular is one I find is frequently not discussed adequately with men in their thirties and forties before they start.
Monitoring is not optional. Baseline assessment, appropriate follow-up labs, and review of whether the intervention is doing what it was started to do are all part of the therapy, not an administrative add-on.
What I see clinically
Patients who come in describing fatigue, poor recovery, and mental fog often arrive already convinced that hormones are the answer. Sometimes they are right. Frequently the picture is more layered.
Sleep quantity and quality is the most common overlooked factor, and untreated sleep apnoea in particular can produce the entire symptom cluster while also suppressing testosterone, which means the low reading is a consequence rather than a cause.
Chronic energy deficit, whether from deliberate restriction or high training volume with inadequate intake, suppresses hormonal output as a predictable adaptation.
Metabolic health interacts with all of it, and I have written separately about why that deserves more attention than it typically gets.
None of this means someone with genuine deficiency should not be treated. It means the evaluation should be an evaluation, not a confirmation. A workup that looks only at hormone levels will find hormone problems, because that is all it was constructed to find.
Reasonable questions to bring to your physician
- What specifically are we treating, and how was it established?
- Has the cause of the deficiency been investigated, rather than just the level?
- What does the evidence support for my situation, as distinct from what is claimed generally?
- What are the risks given my personal and family history?
- What is the monitoring plan, and what would tell us this is not working?
- What are the implications if I want to stop, or if fertility matters to me?
A physician who answers these comfortably is engaging with the actual clinical question. One who responds primarily with benefits is selling something.
Where this leaves the title
Hormone therapy can be a meaningful part of restoring function for people who genuinely need it. Treated as a diagnosis-led medical intervention with real risks and honest monitoring, it is reasonable care.
Treated as a performance product, it is neither well supported nor particularly safe. The difference is not the molecule. It is whether anyone established that you needed it.
Hormone therapy carries risks that vary substantially by individual. Nothing here should be used to start, stop, or adjust treatment. Please consult a qualified physician who can evaluate your history, examination, and laboratory findings.